Open AccessCOST-EFFECTIVENESS ANALYSIS OF CEFTRIAXONE GENERIC AND PATENT IN CHILDREN WITH TYPHOID
Author(s) -
Santi Purna Sari,
Icut Diki Adestia Putri,
Binar Nursanti
Publication year - 2018
Publication title -
international journal of applied pharmaceutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.238
H-Index - 15
ISSN - 0975-7058
DOI - 10.22159/ijap.2018.v10s1.16
Subject(s) - ceftriaxone , medicine , medical prescription , typhoid fever , antibiotics , pharmacology , pathology , microbiology and biotechnology , biology
Objective: This study aimed to measure and compare the effectivity and cost of the two types of ceftriaxone to determine the more cost-effectivetreatment.Methods: In a cross-sectional analytical study, prescription and administrative financial data were retrospectively collected using the total samplingmethod. Data of 63 patients, comprising 43 and 20 patients treated with generic and patent ceftriaxone, respectively, were analyzed. The effectivenessof the treatment was measured in terms of the length of hospital stay of the patients. The total cost of the treatment was the total median of the costsof drugs, laboratory examinations, medical device usage, physician service, and hospitalization.Results: The effectiveness of both generic and patent ceftriaxone was 4 days of hospital stay. Cost-effectiveness ratio of generic ceftriaxone was Rp575,937.25/day and that of patent ceftriaxone was Rp 888,601.75/day.Conclusion: Generic ceftriaxone was more cost-effective than patent ceftriaxone.